• Publications
  • Influence
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
BACKGROUND Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungalExpand
  • 1,025
  • 46
  • PDF
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
BACKGROUND Patients with persistent fever and neutropenia often receive empirical therapy with conventional or liposomal amphotericin B for the prevention and early treatment of invasive fungalExpand
  • 825
  • 45
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
BACKGROUND Infection with Clostridium difficile is the primary infective cause of antibiotic-associated diarrhoea. We aimed to compare efficacy and safety of fidaxomicin and vancomycin to treatExpand
  • 546
  • 22
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update
In 2005, several groups, including the European Group for Blood and Marrow Transplantation, the European Organization for Treatment and Research of Cancer, the European Leukemia Net and theExpand
  • 448
  • 21
  • PDF
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus onExpand
  • 330
  • 19
  • PDF
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections.
The mortality associated with invasive fungal infections remains high with that involving rare yeast pathogens other than Candida being no exception. This is in part due to the severe underlyingExpand
  • 282
  • 18
  • PDF
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.
These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management ofExpand
  • 534
  • 14
  • PDF
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.
As the mortality associated with invasive Candida infections remains high, it is important to make optimal use of available diagnostic tools to initiate antifungal therapy as early as possible and toExpand
  • 295
  • 14
  • PDF
Improved outcome in central nervous system aspergillosis, using voriconazole treatment.
The mortality of central nervous system (CNS) aspergillosis approaches 100%, requiring improved therapies. Voriconazole gives superior efficacy and survival in invasive aspergillosis, compared withExpand
  • 310
  • 13
  • PDF
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
Invasive candidiasis (IC) is a relatively common syndrome in neonates and children and is associated with significant morbidity and mortality. These guidelines provide recommendations for theExpand
  • 193
  • 13
  • PDF